Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy

We compared lesion-based sensitivity of dual-time-point FDG-PET/CT, bone scintigraphy (BS), and low-dose CT (LDCT) for detection of various types of bone metastases in patients with metastatic breast cancer. Prospectively, we included 18 patients with recurrent breast cancer who underwent dual-time-...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jeanette Ansholm Hansen, Mohammad Naghavi-Behzad, Oke Gerke, Christina Baun, Kirsten Falch, Sandra Duvnjak, Abass Alavi, Poul Flemming Høilund-Carlsen, Malene Grubbe Hildebrandt
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/c71ef1f6d0ab4822b57cc9664775fffa
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c71ef1f6d0ab4822b57cc9664775fffa
record_format	dspace
spelling	oai:doaj.org-article:c71ef1f6d0ab4822b57cc9664775fffa2021-11-25T06:19:35ZDiagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy1932-6203https://doaj.org/article/c71ef1f6d0ab4822b57cc9664775fffa2021-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601566/?tool=EBIhttps://doaj.org/toc/1932-6203We compared lesion-based sensitivity of dual-time-point FDG-PET/CT, bone scintigraphy (BS), and low-dose CT (LDCT) for detection of various types of bone metastases in patients with metastatic breast cancer. Prospectively, we included 18 patients with recurrent breast cancer who underwent dual-time-point FDG-PET/CT with LDCT and BS within a median time interval of three days. A total of 488 bone lesions were detected on any of the modalities and were categorized by the LDCT into osteolytic, osteosclerotic, mixed morphologic, and CT-negative lesions. Lesion-based sensitivity was 98.2% (95.4–99.3) and 98.8% (96.8–99.5) for early and delayed FDG-PET/CT, respectively, compared with 79.9% (51.1–93.8) for LDCT, 76.0% (36.3–94.6) for BS, and 98.6% (95.4–99.6) for the combined BS+LDCT. BS detected only 51.2% of osteolytic lesions which was significantly lower than other metastatic types. SUVs were significantly higher for all lesion types on delayed scans than on early scans (P<0.0001). Osteolytic and mixed-type lesions had higher SUVs than osteosclerotic and CT-negative metastases at both time-points. FDG-PET/CT had significantly higher lesion-based sensitivity than LDCT and BS, while a combination of the two yielded sensitivity comparable to that of FDG-PET/CT. Therefore, FDG-PET/CT could be considered as a sensitive one-stop-shop in case of clinical suspicion of bone metastases in breast cancer patients.Jeanette Ansholm HansenMohammad Naghavi-BehzadOke GerkeChristina BaunKirsten FalchSandra DuvnjakAbass AlaviPoul Flemming Høilund-CarlsenMalene Grubbe HildebrandtPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Jeanette Ansholm Hansen Mohammad Naghavi-Behzad Oke Gerke Christina Baun Kirsten Falch Sandra Duvnjak Abass Alavi Poul Flemming Høilund-Carlsen Malene Grubbe Hildebrandt Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
description	We compared lesion-based sensitivity of dual-time-point FDG-PET/CT, bone scintigraphy (BS), and low-dose CT (LDCT) for detection of various types of bone metastases in patients with metastatic breast cancer. Prospectively, we included 18 patients with recurrent breast cancer who underwent dual-time-point FDG-PET/CT with LDCT and BS within a median time interval of three days. A total of 488 bone lesions were detected on any of the modalities and were categorized by the LDCT into osteolytic, osteosclerotic, mixed morphologic, and CT-negative lesions. Lesion-based sensitivity was 98.2% (95.4–99.3) and 98.8% (96.8–99.5) for early and delayed FDG-PET/CT, respectively, compared with 79.9% (51.1–93.8) for LDCT, 76.0% (36.3–94.6) for BS, and 98.6% (95.4–99.6) for the combined BS+LDCT. BS detected only 51.2% of osteolytic lesions which was significantly lower than other metastatic types. SUVs were significantly higher for all lesion types on delayed scans than on early scans (P<0.0001). Osteolytic and mixed-type lesions had higher SUVs than osteosclerotic and CT-negative metastases at both time-points. FDG-PET/CT had significantly higher lesion-based sensitivity than LDCT and BS, while a combination of the two yielded sensitivity comparable to that of FDG-PET/CT. Therefore, FDG-PET/CT could be considered as a sensitive one-stop-shop in case of clinical suspicion of bone metastases in breast cancer patients.
format	article
author	Jeanette Ansholm Hansen Mohammad Naghavi-Behzad Oke Gerke Christina Baun Kirsten Falch Sandra Duvnjak Abass Alavi Poul Flemming Høilund-Carlsen Malene Grubbe Hildebrandt
author_facet	Jeanette Ansholm Hansen Mohammad Naghavi-Behzad Oke Gerke Christina Baun Kirsten Falch Sandra Duvnjak Abass Alavi Poul Flemming Høilund-Carlsen Malene Grubbe Hildebrandt
author_sort	Jeanette Ansholm Hansen
title	Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_short	Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_full	Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_fullStr	Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_full_unstemmed	Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy
title_sort	diagnosis of bone metastases in breast cancer: lesion-based sensitivity of dual-time-point fdg-pet/ct compared to low-dose ct and bone scintigraphy
publisher	Public Library of Science (PLoS)
publishDate	2021
url	https://doaj.org/article/c71ef1f6d0ab4822b57cc9664775fffa
work_keys_str_mv	AT jeanetteansholmhansen diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT mohammadnaghavibehzad diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT okegerke diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT christinabaun diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT kirstenfalch diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT sandraduvnjak diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT abassalavi diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT poulflemminghøilundcarlsen diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy AT malenegrubbehildebrandt diagnosisofbonemetastasesinbreastcancerlesionbasedsensitivityofdualtimepointfdgpetctcomparedtolowdosectandbonescintigraphy
_version_	1718413891411640320

Diagnosis of bone metastases in breast cancer: Lesion-based sensitivity of dual-time-point FDG-PET/CT compared to low-dose CT and bone scintigraphy

Ejemplares similares